INTRODUCTION: Alopecia areata is a common autoimmune disease which results in reversible hair loss. Janus kinase inhibitors are prescribed for severe alopecia areata with encouraging results. There are no studies comparing the efficacy and safety of Janus kinase inhibitors to traditional treatment options, such as topical immunomodulators and traditional immunosuppressants. AIMS: To retrospectively compare the efficacy and safety of baricitinib, an approved Janus kinase inhibitor, to other treatments for severe AA during a 6-month treatment period. MATERIALS/METHODS: We included patients with newly presenting, relapsing or treatment-resistant alopecia areata with Severity of Alopecia Tool (SALT) score ≥ 50, for the period between July 2021 and July 2023. Medical histories were reviewed and possible side effects were recorded. Primary endpoints were SALT ≤ 20 and SALT ≤ 10 after 6 months of treatment. RESULTS: Seventy-five patients (53 females) were divided into three groups: topical immunomodulators (51 patients); baricitinib (19 patients); and a group receiving pulsed intramuscular corticosteroids or traditional immunosuppressants (11 patients). Twenty-one patients received more than one treatment options within 2 years. After 6 months, the baricitinib group showed superior efficacy with 32% and 26% of patients achieving SALT ≤ 20 and SALT ≤ 10, compared to 12% and 9% in both other groups. Baricitinib demonstrated better secondary outcomes (50% and 90% reduction from initial SALT scores). All treatments exhibited mild-to-moderate and expected side effects. Weight gain, which had not been reported in clinical trials for alopecia areata, was observed in three baricitinib-treated patients. CONCLUSION: Baricitinib was superior to traditional treatments for severe alopecia areata after 6 months. Weight gain concerned 16% of patients receiving baricitinib.

Department of Dermatovenerology 3rd Faculty of Medicine Charles University and University Hospital Kralovske Vinohrady Prague Czech Republic

Value Outcomes Prague Czech Republic

See more in PubMed

Villasante Fricke A. C. and Miteva M., “Epidemiology and Burden of Alopecia Areata: A Systematic Review,” Clinical, Cosmetic and Investigational Dermatology 8 (2015): 397–403, 10.2147/CCID.S53985. PubMed DOI PMC

Stefanis A. J., “Janus Kinase Inhibitors in the Treatment of Alopecia Areata,” Prague Medical Report 124, no. 1 (2023): 5–15, 10.14712/23362936.2023.1. PubMed DOI

Stefanis A. J., Arenberger P., Arenbergerova M., and Gkalpakiotis S., “Alopecia Barbae Severity Score: A Novel Scoring System to Estimate the Extent of Beard Loss and Success of Treatment,” British Journal of Dermatology 185, no. 4 (2021): 847–849, 10.1111/bjd.19724. PubMed DOI

Lee H. H., Gwillim E., Patel K. R., et al., “Epidemiology of Alopecia Areata, Ophiasis, Totalis, and Universalis: A Systematic Review and Meta‐Analysis,” Journal of the American Academy of Dermatology 82, no. 3 (2020): 675–682, 10.1016/j.jaad.2019.08.032. PubMed DOI

Lee S., Lee H., Lee C. H., and Lee W. S., “Comorbidities in Alopecia Areata: A Systematic Review and Meta‐Analysis,” Journal of the American Academy of Dermatology 80, no. 2 (2019): 466–477.e16, 10.1016/j.jaad.2018.07.033. PubMed DOI

Strazzulla L. C., Wang E. H. C., Avila L., et al., “Alopecia Areata: An Appraisal of New Treatment Approaches and Overview of Current Therapies,” Journal of the American Academy of Dermatology 78, no. 1 (2018): 15–24, 10.1016/j.jaad.2017.04.1141. PubMed DOI

Olsen E. A., Roberts J., Sperling L., et al., “Objective Outcome Measures: Collecting Meaningful Data on Alopecia Areata,” Journal of the American Academy of Dermatology 79, no. 3 (2018): 470–478.e3, 10.1016/j.jaad.2017.12.008. PubMed DOI PMC

Kwon O., Senna M. M., Sinclair R., et al., “Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata Over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE‐AA1 and BRAVE‐AA2),” American Journal of Clinical Dermatology 24, no. 3 (2023): 443–451, 10.1007/s40257-023-00697-4. PubMed DOI PMC

Wyrwich K. W., Kitchen H., Knight S., et al., “The Alopecia Areata Investigator Global Assessment Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials,” British Journal of Dermatology 183, no. 4 (2020): 702–709, 10.1111/bjd.18814. PubMed DOI PMC

Olayinka J. T. and Richmond J. M., “Immunopathogenesis of Alopecia Areata,” Current Research in Immunology 2 (2021): 7–11, 10.1016/j.crimmu.2021.05.002. PubMed DOI PMC

King B., Ohyama M., Kwon O., et al., “Two Phase 3 Trials of Baricitinib for Alopecia Areata,” New England Journal of Medicine 386, no. 18 (2022): 1687–1699, 10.1056/NEJMoa2110343. PubMed DOI

European Medicines Agency , “Olumiant,” 2023, https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant.

Greco M., De Santo M., Comande A., et al., “Leptin‐Activity Modulators and Their Potential Pharmaceutical Applications,” Biomolecules 11, no. 7 (2021): 1045, 10.3390/biom11071008. PubMed DOI PMC

Patsalos O., Dalton B., and Himmerich H., “Effects of IL‐6 Signaling Pathway Inhibition on Weight and BMI: A Systematic Review and Meta‐Analysis,” International Journal of Molecular Sciences 21, no. 17 (2020): 6290, 10.3390/ijms21176028. PubMed DOI PMC

de Oliveira Micheletti T., Cassia dos Santos A., Rocha G. Z., et al., “Acute Exercise Reduces Feeding by Activating IL‐6/Tubby Axis in the Mouse Hypothalamus,” Frontiers in Physiology 13 (2022): 956116, 10.3389/fphys.2022.879139. PubMed DOI PMC

Arora G., Gupta A., Guo T., et al., “JAK Inhibitors Suppress Cancer Cachexia‐Associated Anorexia and Adipose Wasting in Mice,” JCSM Rapid Communications 3, no. 2 (2020): 115–128, 10.1002/rco2.120. PubMed DOI PMC

European Medicines Agency , “Litfulo,” 2023, https://www.ema.europa.eu/en/medicines/human/EPAR/litfulo.

Martinez‐Molina C., Diaz‐Torne C., Park H. S., Feliu A., Vidal S., and Corominas H., “Tofacitinib and Baricitinib in Type 2 Diabetic Patients With Rheumatoid Arthritis,” Medicina 60, no. 3 (2024): 360, 10.3390/medicina60030001. PubMed DOI PMC

Yabut J. M., Crane J. D., Green A. E., Keating D. J., Khan W. I., and Steinberg G. R., “Emerging Roles for Serotonin in Regulating Metabolism: New Implications for an Ancient Molecule,” Endocrine Reviews 40, no. 4 (2019): 1092–1107, 10.1210/er.2018-00278. PubMed DOI PMC

Nowicka D., Maj J., Jankowska‐Konsur A., and Hryncewicz‐Gwóźdź A., “Efficacy of Diphenylcyclopropenone in Alopecia Areata: A Comparison of Two Treatment Regimens,” Postepy Dermatologii I Alergologii 35, no. 6 (2018): 577–581, 10.5114/ada.2018.79731. PubMed DOI PMC

Wiseman M. C., Shapiro J., MacDonald N., and Lui H., “Predictive Model for Immunotherapy of Alopecia Areata With Diphencyprone,” Archives of Dermatology 137, no. 8 (2001): 1063–1068, 10.1001/archderm.137.8.1063. PubMed DOI

Sotiriadis D., Patsatsi A., Lazaridou E., Kastanis A., Vakirlis E., and Chrysomallis F., “Topical Immunotherapy With Diphenylcyclopropenone in the Treatment of Chronic Extensive Alopecia Areata,” Clinical and Experimental Dermatology 32, no. 1 (2007): 48–51, 10.1111/j.1365-2230.2006.02323.x. PubMed DOI

Abd El‐Magid W. M., Mohamed R. A., and Elsharkawy R. E., “Diphenylcyclopropenone and Platelet‐Rich Plasma in the Management of Severe or Recalcitrant Alopecia Areata,” Journal of Cosmetic Dermatology 22, no. 11 (2023): 2971–2981, 10.1111/jocd.15771. PubMed DOI

Ghandi N., Daneshmand R., Hatami P., et al., “A Randomized Trial of Diphenylcyclopropenone (DPCP) Combined With Anthralin Versus DPCP Alone for Treating Moderate to Severe Alopecia Areata,” International Immunopharmacology 99 (2021): 107971, 10.1016/j.intimp.2021.107971. PubMed DOI

Ibrahim S. A., Esawy A. M., and Abdelshafy A. S., “Treatment of Chronic Extensive Alopecia Areata by Diphenylcyclopropenone Alone Versus in Combination With Anthralin,” Dermatologic Therapy 32, no. 5 (2019): e13010, 10.1111/dth.13010. PubMed DOI

Rastaghi F., Kaveh R., Yazdanpanah N., et al., “The Efficacy and Adverse Effects of Corticosteroid Pulse Therapy in Alopecia Areata: A Review Article,” Dermatology Practical & Conceptual 13, no. 4 (2023): e2023255, 10.5826/dpc.1304a127. PubMed DOI PMC

Staumont‐Salle D., Vonarx M., Lengrand F., et al., “Pulse Corticosteroid Therapy for Alopecia Areata: Long‐Term Outcome After 10 Years,” Dermatology 225, no. 1 (2012): 81–87, 10.1159/000339663. PubMed DOI

Meah N., Wall D., York K., et al., “The Alopecia Areata Consensus of Experts (ACE) Study Part II: Results of an International Expert Opinion on Diagnosis and Laboratory Evaluation for Alopecia Areata,” Journal of the American Academy of Dermatology 84, no. 6 (2021): 1594–1601, 10.1016/j.jaad.2020.12.061. PubMed DOI

Kurosawa M., Nakagawa S., Mizuashi M., et al., “A Comparison of the Efficacy, Relapse Rate and Side Effects Among Three Modalities of Systemic Corticosteroid Therapy for Alopecia Areata,” Dermatology 212, no. 4 (2006): 361–365, 10.1159/000093324. PubMed DOI

Lai V. W. Y., Chen G., Gin D., and Sinclair R., “Cyclosporine for Moderate‐To‐Severe Alopecia Areata: A Double‐Blind, Randomized, Placebo‐Controlled Clinical Trial of Efficacy and Safety,” Journal of the American Academy of Dermatology 81, no. 3 (2019): 694–701, 10.1016/j.jaad.2019.04.054. PubMed DOI

Husein‐ElAhmed H. and Steinhoff M., “Efficacy and Predictive Factors of Cyclosporine A in Alopecia Areata: A Systematic Review With Meta‐Analysis,” Journal of Dermatological Treatment 33, no. 3 (2022): 1643–1651, 10.1080/09546634.2021.1954046. PubMed DOI

Kinoshita‐Ise M., Sachdeva M., Martinez‐Cabriales S. A., Shear N. H., and Lansang P., “Oral Methotrexate Monotherapy for Severe Alopecia Areata: A Single Center Retrospective Case Series,” Journal of Cutaneous Medicine and Surgery 25, no. 5 (2021): 490–497, 10.1177/12034754211013592. PubMed DOI

Joly P., Lafon A., Houivet E., et al., “Efficacy of Methotrexate Alone vs Methotrexate Plus Low‐Dose Prednisone in Patients With Alopecia Areata Totalis or Universalis: A 2‐Step Double‐Blind Randomized Clinical Trial,” JAMA Dermatology 159, no. 4 (2023): 403–410, 10.1001/jamadermatol.2022.5981. PubMed DOI PMC

Ramos P. M., Anzai A., Duque‐Estrada B., et al., “Consensus on the Treatment of Alopecia Areata – Brazilian Society of Dermatology,” Anais Brasileiros de Dermatologia 95, no. Suppl 1 (2020): 39–52, 10.1016/j.abd.2020.04.004. PubMed DOI PMC